| P2093 | author name string | Montaner LJ | |
| P2860 | cites work | Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors | Q28141528 |
| | Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia | Q28254584 |
| | Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy | Q29615992 |
| | Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes | Q29616210 |
| | Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment | Q33799700 |
| | HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy | Q33853859 |
| | Antiretroviral resistance during successful therapy of HIV type 1 infection. | Q33919308 |
| | The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. | Q33971012 |
| | The CD4(+) T cell response to HIV-1. | Q33971030 |
| | What is missing in immunology to understand immunity? | Q34023421 |
| | Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report | Q34024849 |
| | Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes | Q35110576 |
| | HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function | Q35834664 |
| | Infection-immunity in experimental salmonellosis | Q36268349 |
| | Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production | Q36706780 |
| | Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection | Q39601164 |
| | A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors | Q43613003 |
| | Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression | Q43655245 |
| | HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression | Q43750477 |
| | Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient | Q44134443 |
| | Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease | Q45740979 |
| | Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption | Q45740983 |
| | The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy | Q45743180 |
| | Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy | Q45743378 |
| | Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype | Q45745138 |
| | Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. | Q45754658 |
| | Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. | Q52026668 |
| | Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. | Q54029088 |
| | Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. | Q54036214 |
| | Resistance, fitness, adherence, and potency: mapping the paths to virologic failure. | Q54065659 |
| | Control of HIV despite the Discontinuation of Antiretroviral Therapy | Q56851967 |
| | Immune control of HIV-1 after early treatment of acute infection | Q56961920 |
| | Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy | Q57075703 |
| | Control of SIV rebound through structured treatment interruptions during early infection | Q57146531 |
| | Is interruption of HIV therapy always harmful? | Q73413762 |
| | Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease | Q73470103 |
| | Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy | Q74165679 |
| | Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression | Q74310764 |
| | HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group | Q77974277 |
| P433 | issue | 2 | |
| P304 | page(s) | 92-96 | |
| P577 | publication date | 2001-02-01 | |
| P1433 | published in | Trends in Immunology | Q15265730 |
| P1476 | title | Structured treatment interruptions to control HIV-1 and limit drug exposure | |
| P478 | volume | 22 | |